We are very honoured to count MSD Animal Health among the Sponsors of BioFIT 2019

Many thanks to MSD Animal Health for joining BioFIT 2019 as a Silver Sponsor

MSD Animal Health Ventures partners with companies and invests in bringing new solutions to address unmet customer needs, including advanced digital technologies. We are innovators, and we lead by bringing together capabilities across veterinarians, startups, inventors, entrepreneurs, customers and investment partners.

MSD Animal Health Ventures is based in Madison, New Jersey and is actively seeking partnerships and technology investment opportunities.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Advent France Biotechnology, LFB, MSD Animal Health and MSD to have the opportunity to:

Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count MSD Animal Health among the Sponsors of BioFIT 2019 Read More »

We are very honoured to count LFB among the Sponsors of BioFIT 2019

News / Valentine Delabie

Many thanks to LFB for joining BioFIT 2019 as a Contributing Sponsor

Since it was formed in 1994, the LFB has been developing, manufacturing and marketing therapeutic proteins, for diseases that are always serious and often rare. The LFB is now one of the leading European players in biopharmaceutical, its products are aimed at health professionals, mainly hospital-based, these are plasma derived medicinal products in three major fields of therapy: immunology, haemostasis and intensive care. The LFB, a biopharmaceutical company, offers plasma-derived and recombinant medicinal products, and is focused on international growth and an active innovation policy in its fields of therapeutic excellence.
LFB is a public company and is growing in a competitive sector. Over 2000 employees of the LFB, both in France and worldwide, are totally committed to meeting the company mission.
Every year, LFB’s 15 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Advent France Biotechnology, LFB, MSD Animal Health and MSD to have the opportunity to:

Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count LFB among the Sponsors of BioFIT 2019 Read More »

We are very honoured to count Bayer among the Sponsors of BioFIT 2019

News / Valentine Delabie

Many thanks to Bayer for joining BioFIT 2019 as a Bronze Sponsor

Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With their innovative products, they are contributing to finding solutions to some of the major challenges of our time.

With life expectancy continuing to rise, they improve quality of life for a growing population by focusing their research and development activities on preventing, alleviating and treating diseases. They are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.

Their goal is to create value for their customers, stockholders and employees, while also strengthening the company’s earning power. They are committed to operating sustainably and addressing their social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer. All this goes to make up their purpose: Science for a better life.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Advent France Biotechnology, LFB, MSD Animal Health and MSD to have the opportunity to:

Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count Bayer among the Sponsors of BioFIT 2019 Read More »

We are very honoured to count MSD among the Sponsors of BioFIT 2019

News / Valentine Delabie

Many thanks to MSD for joining BioFIT 2019 as a Silver Sponsor

MSD is an innovative, global healthcare leader that is committed to improving health and well-being around the world. Its core product categories include diabetes, cancer, vaccines and hospital acute care. They continue to focus their research on conditions that represent some of today’s most significant health challenges – like cancer, HIV, HPV, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer’s disease, and they are on the front lines in the fight against emerging global pandemics, such as ebola. They also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver their products to the people who need them. At MSD, They’re applying their global reach, financial strength and scientific excellence to do more of what they’re passionate about: improving health and improving lives.

Join key BioFIT 2019 sponsors such as Almirall, Bayer, Boehringer Ingelheim, Novo Nordisk, Advent France Biotechnology, LFB, MSD Animal Health and MSD to have the opportunity to:

Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
Highlight your interest in early-stage innovation
Present your ideas and technologies to key innovation players in Life Sciences
Enhance your visibility on an international scale and be recognised as a key innovative actor
Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

We are very honoured to count MSD among the Sponsors of BioFIT 2019 Read More »

Missed the Early Bird offer? Do not miss the Summer offer!

News / Valentine Delabie

Not registered yet?

Benefit from an exclusive 10% discount on the regular full pass before August 31^st by using the following code:

BioFIT19_Summer_Offer

Missed the Early Bird offer? Do not miss the Summer offer! Read More »

BioFIT 2019 programme is available!

News / Valentine Delabie

BioFIT 2019 programme is available!

Home » News » Page 17

BioFIT 2019 programme is now available

In this brochure, you will find all the information you need about the 8^th edition of the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences.

Download

Continue your tour

Contact

Juliette Vanbastelaere

Event project officer

jvanbastelaere@eurasante.com

+33 9 78 31 61 85

BioFIT 2019 programme is available! Read More »

In-depth interview with Peptomyc, winner of the 2018 Start-up Slams

News / Nadège Joly

Laura Soucek, CEO of Peptomyc, one of the most Innovative Life Sciences Start-up of BioFIT 2018, reveals information on Peptomyc and explains why they attend BioFIT, and in particular why they applied to the Start-up Slams.

What is Peptomyc?

Peptomyc is developing new peptide therapies for the treatment of cancer patients. Our peptides are able to attack Myc, a protein required by cancer cells – but not normal cells -, to divide, thrive and survive treatments. That means that, attacking Myc, we can selectively kill cancer cells without damaging normal tissues.

Why your therapy is innovative?

Our therapy is innovative because 1. nobody has managed to efficiently attack Myc before; 2. because it is effective against cancer but gentle on other tissues, sparing the patient from toxic side effects; and 3. last but not least, because it is potentially applicable to all types of cancer. It is the opposite of personalized medicine: it is universal medicine.

Laura Soucek, CEO of Peptomyc and Marie-Eve Beaulieu, CSO

Why did you apply to the Start-up Slams?

Because it seemed like a great opportunity to gain exposure in one of the biggest events in Europe for early start-ups and investors. It is also a way to take advantage of speed mentoring from the expert juries and a nice platform to establish useful networks.

Why did you attend BioFIT?

We are now in pre-clinical regulatory studies and, if everything goes well, we should be able to start clinical trials at the beginning of 2020. That requires a next round of investment by the end of 2019. At BioFIT we looked for the chance to meet with smart investors that could be interested in our project.

What do you retain from these two days?

It is a very nice specialized conference, which favors informal and formal contacts between start-ups, VCs and CROs. It is less intimidating and more friendly than other international events, especially for early stage biotech companies.

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Go for it! It is a very productive experience and a chance to learn from peers and from expert jury members.

Learn more about the Start-up Slams

In-depth interview with Peptomyc, winner of the 2018 Start-up Slams Read More »

In-depth Interview with Elasmogen, winner of the 2018 Start-up Slams

News / Nadège Joly

Caroline Barelle, CEO of Elasmogen, explains why they attend BioFIT, and in particular why they applied to the Start-up Slams.

Can you describe your innovation in few words?

Next generation therapeutic biologics . These are essentially naturally occurring small antibody-like molecules that form part of the adaptive immune system of sharks. We call these soloMERs.

How is your technology innovative?

Given the small size (better tissue penetration), stability (novel routes of administration), novel structure (binds cryptic or hidden epitopes on the target) and simple structure, the team saw the opportunity to develop these into a new class of therapeutic drugs. We have succeeded in re-formatting these to bind more than one disease target and in isolating soloMERs that bind unique parts of the target disease molecule of all which results in increased potency.

Why did you apply to the Start-up Slams?

The opportunity to headline our company at such a prestigious conference provides the benefit of presenting in front of a great mixed audience of investors, pharma, biotech and academics.

Why did you attend BioFIT?

The quality of participants from all corners of the life science sector

What do you retain from these two days?

I thought it was a great conference. It was the right size to network and reach out and meet those I wanted to. There was the right balance of investors, pharma, biotech and academics there and I was able to benefit from the one-2-one partnering meetings as well as enjoy the panel debates and discussions.

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Go for it! I remain amazed that we were winners given the quality of the other companies but regardless just participating gives you a platform in front of a great panel and a great audience.

More information on www.elasmogen.com

Learn more about the Start-up Slams

In-depth Interview with Elasmogen, winner of the 2018 Start-up Slams Read More »

#BioFIT2019 | Save the date AND THE PLACE

News / Nadège Joly

Save the date and the place: BioFIT | 8^th edition
December 10^th and 11^th, 2019 | Marseille, France

With a record-breaking edition, especially in terms of the number of participants (1,300+ from 35 countries), BioFIT confirms its status as the leading European partnering event for early-stage deals and investment rounds in the field of Life Sciences.

During BioFIT 2018, a unique partnership between three powerful ecosystems – the Sud Provence-Alpes-Côte d’Azur Region, the Grand Est Region and the Hauts-de-France Region – has been announced.

Thanks to a committed collaboration between the competitiveness clusters Eurobiomed, BioValley France and the Nutrition-Health-Longevity cluster, as well as Eurasanté and the local authorities of these three territories, BioFIT will now deploy its anchoring alternately between the cities of Marseille (2019), Strasbourg (2020) and Lille (2021).

Register now and save up to € 150 thanks to the “Super Early Bird” offer!

Download the 2019 brochure

#BioFIT2019 | Save the date AND THE PLACE Read More »

And the winners of the Start-up Slams are …

News / Nadège Joly

The two most innovative start-ups who have been awarded during BioFIT 2018 are:

Emaslogen

Elasmogen Ltd is discovering and developing soloMER™s for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.

www.elasmogen.com

Peptomyc

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

www.peptomyc.com

And the winners of the Start-up Slams are … Read More »

News

BioFIT 2019 programme is available!

Sponsors

Download

Continue your tour

Contact

Juliette Vanbastelaere

What is Peptomyc?

Why your therapy is innovative?

Why did you apply to the Start-up Slams?

Why did you attend BioFIT?

What do you retain from these two days?

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Can you describe your innovation in few words?

How is your technology innovative?

Why did you apply to the Start-up Slams?

Why did you attend BioFIT?

What do you retain from these two days?

What will you say to someone which aims at appling to the Start-up Slams in 2019?

Save the date and the place: BioFIT | 8th edition December 10th and 11th, 2019 | Marseille, France

Emaslogen

Peptomyc

Save the date and the place: BioFIT | 8^th edition
December 10^th and 11^th, 2019 | Marseille, France